Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its peers? We will compare Oruka ...

Stifel has launched its coverage on pre-clinical stage biotech Oruka Therapeutics (NASDAQ:ORKA) with a buy recommendation and ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque ...

Oruka Therapeutics (ORKA) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren. Tyler Van Buren’s rating is based on Oruka Therapeutics’ advanced monoclonal antibody ...

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002.

MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases ...